A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a diffuse (>90% body surface area) cutaneous rash and was characterized by intensely pruriginous dusky nodules (n = 10) and red flat-topped papules (n = 60). No response to topical corticosteroids and psoralen plus ultraviolet A (PUVA) phototherapy was observed. In order to effectively treat progressive TP53-mutated CLL, the potent BCL2 inhibitor, venetoclax, was initiated with no treatment-related complications. While CLL only achieved a partial response, a complete remission of LyP-associated cutaneous rash and of the intractable pruritus was obtained within 2 months from venetoclax initiation. BCL2 immunostaining of the original cutaneous specimen showed a strong over-expression of the anti-apoptotic protein, restricted to CD30+ lymphoid cells and reactive microenvironment. At 12 months follow-up, the patient is still in complete remission of LyP. Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of venetoclax for the treatment of this primary cutaneous CD30+ lymphoproliferative disorder, especially in the setting of severe and refractory disease.

Keywords: T-cell lymphoma, chronic lymphocytic leukemia, venetoclax (BCL2 inhibitor), lymphomatoid papulosis (LyP), lymphomatoid papulosis treatment

INTRODUCTION

Lymphomatoid papulosis (LyP) is a primary cutaneous CD30+ T-cell lymphoproliferative disorder characterized by chronic, recurrent, and self-healing papulonecrotic or nodular skin lesions, generally localized to the trunk and extremities (1). LyP accounts for ~12% of cutaneous T-cell lymphomas (CTCLs) and usually exhibits a benign course (as some cases can regress...
With a 5-year disease-specific survival of 99% (1). In ~20% of patients, LyP may be preceded by, associates with, or followed by another malignant lymphoma such as mycosis fungoides, anaplastic large T-cell lymphoma, or, more rarely, Hodgkin’s lymphoma (1); however, LyP has been anecdotally reported in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), only accounting for 11 adult cases previously described (2).

LyP has no approved therapy and can often be very difficult to treat, especially in the presence of extensive and ulcerative lesions or chronic intractable pruritus (1, 3); recently, brentuximab vedotin, a monoclonal antibody directed against CD30, has proved effective in treating refractory LyP in a phase II trial (4, 5), achieving an overall response rate in 12/12 cases [100%] and a complete response rate in 5/12 cases [58%]; however, its use in the clinic might be limited (at least in part) by peripheral neuropathy [10/12 cases (83%) and 5/12 cases (42%) experienced grade 2 neuropathy (5)].

**CASE PRESENTATION**

In June 2014, a 57-year-old Caucasian man was diagnosed with chronic lymphocytic leukemia (CLL), Rai stage II, Binet stage A, genetically driven by an unmutated immunoglobulin variable heavy-chain (IGHV) gene status, with no mutations in NOTCH1, SF3B1, and TP53 genes; interphase fluorescence in situ hybridization (I-FISH) performed with the peripheral blood lymphocytes identified a IGHV/14q32 deletion and no other cytogenetic aberrations. CLL B cells did not express zeta chain-associated protein kinase 70 (ZAP70) and CD38. Blood counts showed lymphocytosis (lymphocyte absolute count: 8,500 × 10^9/L) and no anemia or thrombocytopenia. The patient underwent a careful clinical and laboratory follow-up for ~4.5 years. In January 2019, CLL progressed with notable lymphocytosis (331,000 × 10^9/L) and macrocytic anemia [Hb 11.2 g/dl, mean corpuscular volume (MCV) 112 fl], accompanied with supra-/subdiaphragmatic lymphadenopathies (>3 regions) and splenomegaly (longitudinal spleen diameter of 22 cm); no TP53 mutations/deletion underlay disease progression. Chemoimmunotherapy with intravenous bendamustine (90 mg/m², days 1 and 2) and rituximab (375 mg/m², day 1) was then administered (for 6 cycles, every 28 days, from January to July 2019), achieving a partial response (6). In August 2019, the patient presented with a skin rash of intensely pruritic dusky nodules (n > 10) and red flat-topped papules (n > 300) with erythema involving >90% of body surface area ([Figures 1A–D]).

The punch biopsy specimen obtained from the left arm and stained with hematoxylin and eosin demonstrated an abnormal mixed-lymphoid infiltrate (composed of small lymphocytes and few large-sized Hodgkin-like cells) in the dermis and subcutis, with moderate extension into epidermis ([Figure 2A]). Immunohistochemical analysis showed that pathological Hodgkin-like cells were CD3+, CD4+, CD30+ ([Figure 2B]) and CD8−, and were intermingled with numerous inflammatory cells (mostly of T-cell origin; [Figure 2C]); no monomorphic small
neoplastic B cells nor immunoglobulin gene rearrangements were detected in the skin biopsy, thus excluding a diagnosis of B-cell leukemia cutis while proving that the CD30+ cutaneous lymphoproliferative disorder was clonally unrelated to the mature B-cell neoplasm in our case. In conclusion, the clinicopathological picture was consistent with mixed-infiltrate type A LyP (1).

Topical corticosteroid beclomethasone (from August 2019 to January 2020) and psoralen plus ultraviolet A (PUVA) phototherapy were administered (three times per week, from January to April 2020) with no improvement of the diffuse skin papulonodular rash nor of the intractable pruritus associated with scratch lesions [pruritus was defined as of severe entity, according to a visual analogue scale (7)]. In April 2020, a second progression of CLL occurred and it was clinically characterized by progressive lymphadenopathy and, genetically, by the acquisition of a pathogenic nonsense mutation (TP53<sup>E294X</sup>) and of a monoallelic deletion of TP53 gene (delTP53/17p11). A salvage therapy with oral venetoclax (400 mg, daily, following the 5-week ramp-up dosing schedule), a potent selective BCL2 inhibitor, was then started and induced a partial response of CLL (6) with no treatment-related complications (in particular, no tumor lysis syndrome or neutropenia); owing to the risk of cardiotoxicity, the administration of Bruton’s tyrosine kinase inhibitor, ibrutinib, was not considered in this patient who had recently suffered acute myocardial infarction. Very surprisingly, LyP-associated skin lesions completely resolved (zero lesions) along with intractable pruritus within 8 weeks from venetoclax initiation (Figures 1E–H).

DISCUSSION

In order to search for the molecular underpinning of patient’s dramatic response to venetoclax, we stained the original cutaneous biopsy for the BCL2 anti-apoptotic protein and demonstrated its strong expression restricted to the CD30+ Hodgkin-like cell component (Figure 2D); a positive staining for BCL2 has been previously described in 100% of LyP cases studied by immunohistochemistry [8 and 5 cases from two independent studies (8, 9)], and it has been mostly observed within the reactive small T-cell infiltrate of the LyP tissue (13/13); however, only in 1/8 cases (~12%), BCL2 over-expression has been even detected in the Hodgkin-like cell component (9), as it is for the current case. Notably, BCL2 protein and mRNA expression have shown to have an inverse relationship with in vitro sensitivity to venetoclax in primary cells from patients with CTCL, and a higher BCL2 expression at baseline does correlate with a better response to venetoclax (10); these observations are in line with the patient’s durable complete response to venetoclax (lasting >12 months from drug initiation and still present in May 2021), which is defined as no detectable active skin lesion (11).

CONCLUDING REMARKS

Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of the BCL2 inhibitor,
venetoclax, for the treatment of this primary cutaneous CD30+ lymphoproliferative disorder, especially in the setting of severe and refractory disease.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

1. Willemze R, Cerroni L, Kempf, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 Update of the WHO–EORTC Classification for Primary Cutaneous Lymphomas. Blood (2019) 133(16):1703–14. doi: 10.1182/blood-2018-11-881268
2. Cheng JW, Cohen PR. Lymphomatoid Papulosis in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Case Report and Literature Review. Dermatol Online J (2018) 24(5):13030/qt0n77015.
3. Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ, et al. CD30-Positive Primary Cutaneous Lymphoproliferative Disorders: Molecular Alterations and Targeted Therapies. Haematologica (2019) 104 (2):226–35. doi: 10.3324/haematol.2018.197152
4. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol (2015) 33(32):3759–65. doi: 10.1200/ JCO.2014.60.3787
5. Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol (2017) 153(12):1302–6. doi: 10.1001/ jamadermatol.2017.3593
6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Döhner H, et al. iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL. Blood (2018) 131 (25):2745–60. doi: 10.1182/blood-2017-09-806398
7. Reich A, Heissig M, Pfan NQ, Tanaka K, Takamori K, Takeuchi S, et al. Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus. Acta Derm Venerol (2012) 92:497–501. doi: 10.2340/00015555-1265
8. Dummer R, Michie SA, Kell D, Gould JW, Haefner AC, Smoller BR, et al. Expression of Bcl-2 Protein and Ki-67 Nuclear Proliferation Antigen in Benign and Malignant Cutaneous T-Cell Infiltrates. J Cutan Pathol (1995) 22(1):1–7.
9. Pauli M, Berti E, Boveri E, Kindl S, Bonoldi E, Gambini C, et al. Cutaneous CD30+ Lymphoproliferative Disorders: Expression of Bcl-2 and Proteins of the Tumor Necrosis Factor Receptor Superfamily. Hum Pathol (1998) 29 (11):1223–30.
10. Cyrenne BM, Lewis JM, Weed GM, Carlson KR, Mirza FN, Foss FM, et al. Synergy of BCL2 and Histone Deacetylase Inhibition Against Leukemic Cells From Cutaneous T-Cell Lymphoma Patients. Blood (2017) 130(19):2073–83. doi: 10.1182/blood-2017-06-792150
11. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol (2011) 29(18):2598–607. doi: 10.1200/ JCO.2010.32.0630

**AUTHOR CONTRIBUTIONS**

VG, AM, and PS conceived the study. VG, VC, MB, and PS were involved in patient’s clinical management and treatment. VG, GM, SA, AM, and PS performed the pathological examination of the skin biopsy. ED, FDF, CR, and DS performed molecular genetic analyses. VG, AM, and PS wrote the paper. AM and PS supervised the entire study. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research has received funding from the Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 2018, Project ID 21352, to PS.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Guarente, Martino, Dorillo, De Falco, Rompietti, Sorcini, Brogna, Cardinali, Ascani, Marra and Sportoletti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.